A USFDA warning letter to an Indian company is a formal notice from the US Food and Drug Administration's drug center (CDER) that a facility in India violated current good manufacturing practice (CGMP), which makes its drugs adulterated under US law until the firm fixes the problems. Between January 1, 2025 and October 14, 2026, FDA sent 34 such letters to Indian facilities. This page lists every one, with the city, product type and charges, counted from the Atlas warning letter data pulled on October 21, 2026.
Each row was checked against the letter itself, so the state is where FDA inspected, which is often a different city from the head office that received the letter.
Key facts:
- FDA issued 34 CGMP warning letters to facilities in India from January 1, 2025 to October 14, 2026: 16 in 2025 and 18 so far in 2026 (Atlas count, data pulled October 21, 2026).
- Of the 206 CDER warning letters with CGMP in the subject line in that window, India received 33, behind the United States (99) and ahead of China (31).
- 16 letters went to active pharmaceutical ingredient (API) makers, 15 to finished-drug facilities and 3 to contract testing laboratories.
- FDA cited a quality unit failure in 23 of the 34 letters, and 16 letters state that the facility was already on Import Alert 66-40.
- For the 31 letters that followed an inspection, the median gap from the last inspection day to the letter was 174 days.

Which Indian companies got FDA warning letters in 2026?
Eighteen Indian facilities received FDA CGMP warning letters in 2026 through October 14, from Cohance Lifesciences in January to Reliance Life Sciences and Shoolin Pharma Chem on August 18, 2026, the latest India letter in the data. The 2025 letters number 16. The table lists all 34, oldest first, with links to each facility's Atlas record where that page is public.
| Company | Facility city, state | Letter date | Product type | Main charges |
|---|---|---|---|---|
| Global Calcium Pvt. Limited | Hosur, Tamil Nadu | Jan 16, 2025 | API | Quality unit document control, facility upkeep, no impurity profile |
| Jagsonpal Pharmaceuticals Limited | Bhiwadi, Rajasthan | Feb 5, 2025 | API made at a contract site | Quality unit oversight of the contract manufacturer, drug listing |
| Tyche Industries Ltd | Kakinada, Andhra Pradesh | Feb 6, 2025 | API | Records not made at the time of work, cleaning carry-over, no identity testing |
| Granules India Limited | Gagillapur, Telangana | Feb 26, 2025 | Finished drugs | Cleaning and maintenance (211.67(b)), building repair (211.58), calibration |
| Shree Jaya Laboratories Pvt. Ltd. | Choutuppal, Telangana | Feb 28, 2025 | API intermediates | Cleaning carry-over, complaint investigations, quality unit |
| Aspen Biopharma Labs Pvt. Ltd. | Hyderabad, Telangana | Mar 5, 2025 | API | Facility design, process and cleaning validation, records, stability |
| Macsen Drugs | Udaipur, Rajasthan | Mar 5, 2025 | API | Quality unit, stability data for retest dates |
| Mentha & Allied Products Pvt. Ltd. | Rampur, Uttar Pradesh | Apr 16, 2025 | API | Facility upkeep, quality unit, identity testing, process validation |
| Healwell Homeo Pvt. Ltd. | Mehsana district, Gujarat | Jun 12, 2025 | Homeopathic and OTC drugs | Component identity testing (211.84), quality unit (211.22) |
| Kenil Healthcare Pvt. Ltd. | Kadi, Mehsana, Gujarat | Jun 12, 2025 | OTC drugs | Equipment cleaning (211.67(a)), space (211.42(b)), quality unit |
| Glenmark Pharmaceuticals Limited | Pithampur, Madhya Pradesh | Jul 11, 2025 | Finished drugs | Investigations (211.192), stability program (211.166(a)), lab controls |
| Shiva Analyticals (India) Pvt. Ltd. | Hoskote, Karnataka | Jul 23, 2025 | Contract testing lab | Investigations (211.192), quality control unit procedures (211.22(d)) |
| Hikal Limited | Jigani, Karnataka | Aug 20, 2025 | API | Complaint investigations, supplier evaluation |
| Cdymax (India) Pharma Pvt. Ltd. | Jigani, Karnataka | Nov 13, 2025 | API | Out-of-specification investigations, test methods |
| Seema International | New Delhi, Delhi | Nov 13, 2025 | API | Cleaning carry-over, stability program, quality unit |
| Chemspec Chemicals Pvt. Ltd. | Panvel, Navi Mumbai, Maharashtra | Dec 23, 2025 | API | Quality unit and data integrity: missing batch records, replaced pages |
| Cohance Lifesciences Limited | Nacharam, Hyderabad, Telangana | Jan 30, 2026 | Finished drugs | Investigations (211.192), cleaning (211.67(a) and (b)) |
| Tentamus India Pvt. Ltd. | Hyderabad, Telangana | Mar 3, 2026 | Contract testing lab | Quality control unit, investigations, lab records (211.160(a)) |
| Flowchem Pharma Pvt. Ltd. | Hindupur, Andhra Pradesh | Mar 11, 2026 | API | Cleaning, storage, impurity profile, identity testing |
| Patcos Cosmetics Pvt. Ltd. | Daman, Dadra and Nagar Haveli and Daman and Diu | Mar 12, 2026 | OTC drugs | Building repair, identity testing, production controls, quality unit |
| Intas Pharmaceuticals Limited | Selaqui, Dehradun, Uttarakhand | Mar 30, 2026 | Finished drugs | Out-of-specification investigations (211.192), quality unit (211.22) |
| Alchymars ICM SM Pvt. Ltd. | Alathur, Tamil Nadu | May 21, 2026 | API | Equipment maintenance, building upkeep |
| Gopaldas Visram & Co., Ltd. | Navi Mumbai, Maharashtra | Jun 2, 2026 | OTC drugs, records review | Quality unit and investigations, talc testing, component release |
| Umendra Life Sciences Pvt. Ltd. | Ahmedabad, Gujarat | Jun 2, 2026 | OTC drugs, records review | Quality unit, component testing (211.84(d)) |
| Zydus Lifesciences Limited | Baddi, Himachal Pradesh | Jun 2, 2026 | Prescription drugs with talc, records review | Component testing (211.84), quality unit |
| Wizcure Pharmaa Pvt. Ltd. | Bhiwadi, Rajasthan | Jun 24, 2026 | Sterile drugs | Incomplete lab data (211.194(a)), aseptic areas, sterile validation, cleaning |
| Almon Healthcare Pvt. Ltd. | Bavla, Ahmedabad, Gujarat | Jul 13, 2026 | API and intermediates | Quality unit, test methods, cleaning |
| BioMylz Pvt. Ltd. | Bengaluru, Karnataka | Jul 13, 2026 | Finished drugs, contract manufacturer | Quality unit, production procedures, lab controls |
| Shimoga Chemicals | Sangli, Maharashtra | Jul 13, 2026 | API | Test methods, process validation, quality unit |
| Dabur India Limited | Silvassa, Dadra and Nagar Haveli and Daman and Diu | Jul 24, 2026 | OTC drugs | Quality unit (falsified logbook), incomplete lab data, cleaning |
| Auriga Research Pvt. Ltd. | Bengaluru, Karnataka | Aug 12, 2026 | Contract testing lab | Incomplete lab data (211.194(a)), quality control unit procedures |
| Eugia Pharma Specialities Limited, Unit 1 | Kolthur, Telangana | Aug 13, 2026 | Sterile drugs | Aseptic area design (211.42(c)(10)), sterile process validation (211.113(b)) |
| Reliance Life Sciences Pvt. Ltd. | Navi Mumbai, Maharashtra | Aug 18, 2026 | Sterile drugs | Incomplete lab data (211.194(a)), sterile process controls (211.113(b)) |
| Shoolin Pharma Chem LLP | Indrad, Mehsana, Gujarat | Aug 18, 2026 | API | Cleaning, incomplete lab records, stability, quality unit |
Sources: each FDA warning letter (letter dates, facility addresses and numbered violations) and the Atlas warning letter data pulled October 21, 2026. Names without a link have no indexed Atlas facility page yet. One more CDER letter, to Zenzi Pharmaceutical Industries in Thane on February 13, 2025, charged the firm with refusing a records request rather than with CGMP violations, so it sits outside the count.
Some names carry longer histories that this list does not repeat. Our Granules India inspection history covers the Gagillapur letter in detail, and the Reliance Life Sciences warning letter has its own breakdown. Letters from before 2025, such as the December 2024 letter to Mylan's Indore facility, appear in our Mylan and Viatris India history and the Hetero Labs inspection history.
How many FDA warning letters did India get by year and state?
India received 16 FDA CGMP warning letters in 2025 and 18 in 2026 through October 14, so 2026 passed the full 2025 total by mid August. Telangana (6), Karnataka (5) and Gujarat (5) account for 16 of the 34. Maharashtra had 4 and Rajasthan 3.

China's count fell while India's held. Among CDER letters with CGMP in the subject line, China went from 22 in 2025 to 9 in 2026 through October 14, while India went from 16 to 17 (the 18th India letter, to Patcos, uses a different subject line). Over the whole window the counts are United States 99, India 33 and China 31.
By product, API makers took 16 letters. Finished-drug facilities took 15, of which 6 make over-the-counter (OTC) drugs and 3 make sterile drugs. Three letters went to contract testing laboratories in Bengaluru, Hoskote and Hyderabad, a group FDA treats as an extension of the manufacturer.

What do FDA warning letters to Indian facilities cite?
FDA warning letters to Indian facilities cite the quality unit more than anything else: 23 of the 34 letters name a quality unit failure under 21 CFR 211.22 or the API quality unit duty. Data integrity comes second, with 18 letters asking for a data integrity remediation, then cleaning (12), investigations (9), component identity testing (8) and stability (5).

The themes overlap. In the Dabur letter of July 24, 2026, FDA described a quality unit that signed records with values that did not match the analysts' data books, and an equipment logbook rewritten before it reached the investigator.

Cleaning findings cluster in API letters. Seven of the 12 cleaning citations sit in API letters, where FDA writes "failure to clean equipment and utensils to prevent contamination or carry-over." Finished-drug letters cite 21 CFR 211.67 instead. The Granules letter of February 26, 2025 is the clearest case: investigators found contamination in ducts serving non-dedicated equipment, and the firm's own reserve sample testing confirmed cross-contamination.

Three letters dated June 2, 2026, to Gopaldas Visram, Umendra Life Sciences and Zydus Lifesciences, came from records alone. FDA sent section 704(a)(4) requests in August and November 2025 and wrote the letters from what the firms sent back. Two of them, Gopaldas and Zydus, concern talc used in drug products and how the firms tested it for asbestos.
Repeat findings get their own section. The Chemspec letter has a section on repeat observations at the facility, and the Eugia and Glenmark letters each note repeat violations at multiple sites. The Atlas record for Alchymars ICM SM (release of August 15, 2026) shows seven FDA inspections from 2008 to 2025, and every one ended with a Form 483.
What are the recent FDA 483 observations made in India?
The most frequent recent FDA 483 observation in India is 21 CFR 211.22(d), quality control unit procedures not in writing or not followed, cited in 19 of 47 drug inspections (40%) with posted citations between January 24, 2025 and June 30, 2026. Investigations under 211.192 follow at 16 (34%), then cleaning under 211.67(a) at 12 (26%).
| 21 CFR section | What it covers | India drug inspections citing it | Share of 47 |
|---|---|---|---|
| 211.22(d) | Quality control unit procedures not in writing or followed | 19 | 40% |
| 211.192 | Investigations of discrepancies and failures | 16 | 34% |
| 211.67(a) | Equipment cleaning, sanitizing and maintenance | 12 | 26% |
| 211.160(b) | Scientifically sound laboratory controls | 10 | 21% |
| 211.113(b) | Sterile drug procedures and validation | 10 | 21% |
Source: FDA inspection citation data for drug inspections at Indian facilities, as held in the Atlas data pulled October 21, 2026. A Form 483 lists observations, and only some inspections end in a letter. The same sections run through the letters above, which is why the 483 is the best early read on a supplier.
Single 483s show the detail behind those totals. At Shiva Analyticals, the January 2025 Form 483 cites 211.160(b), 211.192 and 211.198(a), and the July 2025 warning letter leads with 211.192. To see who signs these forms, our list of FDA investigators in India ranks the investigators behind Indian 483s, and the FDA facility database shows any site's inspections and outcomes.
If a supplier on this list makes your API or tests your batches, its last Form 483 and the investigator who wrote it tell you what the next visit will check.
See what the FDA knows about your next investigator.
30 minutes with the founder. No pitch deck.
How long after an inspection does an Indian facility get a warning letter?
An Indian facility that receives an FDA warning letter gets it a median of 174 days after the inspection ends, based on the 31 letters in 2025 and 2026 that followed an on-site inspection. The fastest was Shoolin Pharma Chem at 123 days. The slowest was Jagsonpal Pharmaceuticals at 308 days, after an inspection spread over three dates in 2024.

The import alert often lands first. Sixteen of the 34 letters state the facility is on Import Alert 66-40, and in all 16 FDA listed the facility before the letter date: Dabur on June 5, 2026 and its letter on July 24, Shoolin on August 11 and its letter on August 18. Our guide to Import Alert 66-40 and its 2026 warning letters explains that sequence and how firms get off the list.
The classification step decides which facilities enter that path. Of 384 FDA drug inspections at Indian facilities that ended between January 2, 2025 and October 14, 2026, 41 were classified Official Action Indicated (OAI), a rate of 10.7%. The US rate over the same window was 11.8% (231 of 1,951). FDA posts classifications after a lag, so the 2026 figures will still move.
FDA keeps inspecting after a letter. Global Calcium received its letter in January 2025, and Atlas shows FDA back at the Hosur facility from January 27 to February 3, 2026, ending with another Form 483. Intas shows four inspections at Selaqui, three with a 483, and its 2023 inspection also led to a letter.
Is a 483 a warning letter?
A Form 483 is not a warning letter. The Form 483 lists inspectional observations that an investigator hands to the facility at the end of an inspection, and it is not a final agency finding. A warning letter comes later from CDER, after FDA reviews the 483, the firm's response and the classification, and states that the drugs are adulterated.
| Form 483 | Warning letter | |
|---|---|---|
| Issued by | The investigator, at the close-out meeting | CDER, months later (median 174 days for India) |
| Legal weight | Observations, not a final finding | Formal notice of violations; drugs called adulterated |
| Response | Expected within 15 business days | Required within 15 business days |
| Public | Released on request or by FDA posting | Posted on FDA's warning letter page |
Our explainer on responding to a 483 vs a warning letter covers how the two responses differ.
Where can I find FDA warning letters?
FDA posts warning letters on its warning letter page, searchable by company, subject, issuing office and date, usually within weeks of the letter date. The page has no country filter, so finding the letters to Indian firms means reading the address in each letter, which is how this list was built.
Our FDA warning letter database guide explains the fields and how to connect a letter to the Form 483 behind it. Indian manufacturers that work to India's own GMP rules can compare them with US expectations in our guide to Schedule M.
A weekly read of new Form 483s and warning letters is the earliest signal you get that a supplier is heading toward this table.
FDA Inspection Intelligence Digest
We track every 483, EIR, and warning letter the moment it happens. Get the signals before they hit the FDA website.
Frequently asked questions
An Indian company has 15 working days from receipt to answer an FDA warning letter in writing. The response should describe the investigation, the root causes, the corrective actions with dates, and any action on product already shipped to the US. If the fixes take longer, FDA expects a timeline and then progress updates until the work is done.

Written by
Bhavish Agarwal
Founder, Atlas
Bhavish Agarwal is the founder of Atlas and previously worked at Google and Microsoft. He has spent the past several years building regulatory data infrastructure for the pharmaceutical industry.

